{'52WeekChange': 0.81183755,
 'SandP52WeekChange': None,
 'address1': '490 Arsenal Way',
 'address2': 'Suite 120',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.98,
 'askSize': 800,
 'averageDailyVolume10Day': 749562,
 'averageVolume': 1035066,
 'averageVolume10days': 749562,
 'beta': 0.329849,
 'beta3Year': None,
 'bid': 9.61,
 'bidSize': 1100,
 'bookValue': 2.592,
 'category': None,
 'circulatingSupply': None,
 'city': 'Watertown',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 10.13,
 'dayLow': 9.64,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.351,
 'enterpriseToRevenue': 77.482,
 'enterpriseValue': 446220320,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '781 642 0399',
 'fiftyDayAverage': 11.487286,
 'fiftyTwoWeekHigh': 14.68,
 'fiftyTwoWeekLow': 3.24,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 33192176,
 'forwardEps': -1.4,
 'forwardPE': -6.9428573,
 'fromCurrency': None,
 'fullTimeEmployees': 136,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00977,
 'heldPercentInstitutions': 0.67190003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kalarx.com',
 'longBusinessSummary': 'Kala Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, focuses on the development and '
                        'commercialization of therapies using its proprietary '
                        'nanoparticle-based Mucus Penetrating Particles (MPP) '
                        'technology for the treatment of eye diseases. The '
                        "company's lead product candidate is KPI-121 0.25% "
                        'which has completed two Phase III clinical trials for '
                        'the treatment of temporary relief of the signs and '
                        'symptoms of dry eye disease; INVELTYS which has '
                        'completed two Phase III clinical trials for the '
                        'treatment of inflammation and pain following ocular '
                        'surgery; and KPI-285, a MPP receptor tyrosine kinase '
                        'inhibitor program, which is in preclinical studies '
                        'for the treatment of retinal diseases. The company '
                        'was formerly known as Hanes Newco, Inc. and changed '
                        'its name to Kala Pharmaceuticals, Inc. in December '
                        '2009. Kala Pharmaceuticals, Inc. was founded in 2009 '
                        'and is headquartered in Watertown, Massachusetts.',
 'longName': 'Kala Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 541558592,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_83652421',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -90914000,
 'nextFiscalYearEnd': 1640908800,
 'open': 10.13,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.08,
 'phone': '781 996 5252',
 'previousClose': 10.255,
 'priceHint': 2,
 'priceToBook': 3.75,
 'priceToSalesTrailing12Months': 94.03691,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 10.13,
 'regularMarketDayLow': 9.64,
 'regularMarketOpen': 10.13,
 'regularMarketPreviousClose': 10.255,
 'regularMarketPrice': 10.13,
 'regularMarketVolume': 1194827,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 55715900,
 'sharesPercentSharesOut': 0.0932,
 'sharesShort': 5194943,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3737125,
 'shortName': 'Kala Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1325,
 'shortRatio': 4.35,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'KALA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.53,
 'twoHundredDayAverage': 9.190612,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '06a09f76-df06-3807-bce5-79032313c0fe',
 'volume': 1194827,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.kalarx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02472'}